协和医学杂志
協和醫學雜誌
협화의학잡지
MEDICAL JOURNAL OF PEKING UNION MEDICAL COLLEGE HOSPITAL
2014年
4期
384-388
,共5页
马明圣%张续德%魏珉%赵时敏%邱正庆
馬明聖%張續德%魏珉%趙時敏%邱正慶
마명골%장속덕%위민%조시민%구정경
Duchenne型肌营养不良%糖皮质激素%泼尼松%治疗
Duchenne型肌營養不良%糖皮質激素%潑尼鬆%治療
Duchenne형기영양불량%당피질격소%발니송%치료
Duchenne muscular dystrophy%glucocorticoid%prednisone%treatment
目的:评估短期应用小剂量糖皮质激素是否具有提高Duchenne型肌营养不良(Duchenne muscular dystrophy, DMD)患儿肌力和运动功能的作用。方法纳入2005年9月至2008年12月北京协和医院明确诊断的5~10岁DMD患儿。试验采取随机、双盲、对照的原则,分为治疗组和对照组。治疗组患儿给予泼尼松0.75 mg/(kg· d),对照组给予维生素C 0.3 mg/d。治疗时间为3个月,每隔1个月随访1次,随访3个月,评估4次就诊时的肌力、运动功能、肺功能和肌酸激酶。结果共31例DMD患儿纳入研究,其中治疗组17例,对照组14例。对照组患儿4次就诊的平均肌力评分依次为38.2±7.5、37.0±8.0、36.2±7.6、36.6±7.7,治疗组为37.7±6.1、39.1±6.4、40.3±5.9、40.0±5.6,两组治疗1、2、3个月后与治疗前肌力的差值比较,差异均有统计学意义(P=0.024, P=0.000, P=0.002)。对照组4次就诊行走9 m的平均时间依次为(7.7±2.5)、(7.6±2.8)、(8.1±2.4)、(7.6±2.8) s,治疗组为(8.5±3.4)、(7.2±3.3)、(7.6±3.1)、(7.1±2.8) s,两组治疗2、3个月后与治疗前行走9 m所用时间的差值比较,差异均有统计学意义(P=0.013, P=0.003)。对照组4次就诊的平均用力肺活量(forced vital capacity, FVC)依次为(1.24±0.28)、(1.13±0.26)、(1.21±0.31)、(1.16±0.26) L,治疗组为(1.14±0.37)、(1.40±0.35)、(1.42±0.36)、(1.52±0.37) L,两组治疗1、2、3个月后与治疗前FVC的差值比较,差异均有统计学意义(P=0.000, P=0.006, P=0.000)。两组治疗1个月后与治疗前的肌酸激酶的差值比较,差异亦有统计学意义( P=0.035)。3个月后治疗组激素不良反应仅表现为体重增加,无其他严重不良反应。结论短期应用小剂量泼尼松治疗DMD可以增加患儿肌力,改善患儿运动及肺功能。
目的:評估短期應用小劑量糖皮質激素是否具有提高Duchenne型肌營養不良(Duchenne muscular dystrophy, DMD)患兒肌力和運動功能的作用。方法納入2005年9月至2008年12月北京協和醫院明確診斷的5~10歲DMD患兒。試驗採取隨機、雙盲、對照的原則,分為治療組和對照組。治療組患兒給予潑尼鬆0.75 mg/(kg· d),對照組給予維生素C 0.3 mg/d。治療時間為3箇月,每隔1箇月隨訪1次,隨訪3箇月,評估4次就診時的肌力、運動功能、肺功能和肌痠激酶。結果共31例DMD患兒納入研究,其中治療組17例,對照組14例。對照組患兒4次就診的平均肌力評分依次為38.2±7.5、37.0±8.0、36.2±7.6、36.6±7.7,治療組為37.7±6.1、39.1±6.4、40.3±5.9、40.0±5.6,兩組治療1、2、3箇月後與治療前肌力的差值比較,差異均有統計學意義(P=0.024, P=0.000, P=0.002)。對照組4次就診行走9 m的平均時間依次為(7.7±2.5)、(7.6±2.8)、(8.1±2.4)、(7.6±2.8) s,治療組為(8.5±3.4)、(7.2±3.3)、(7.6±3.1)、(7.1±2.8) s,兩組治療2、3箇月後與治療前行走9 m所用時間的差值比較,差異均有統計學意義(P=0.013, P=0.003)。對照組4次就診的平均用力肺活量(forced vital capacity, FVC)依次為(1.24±0.28)、(1.13±0.26)、(1.21±0.31)、(1.16±0.26) L,治療組為(1.14±0.37)、(1.40±0.35)、(1.42±0.36)、(1.52±0.37) L,兩組治療1、2、3箇月後與治療前FVC的差值比較,差異均有統計學意義(P=0.000, P=0.006, P=0.000)。兩組治療1箇月後與治療前的肌痠激酶的差值比較,差異亦有統計學意義( P=0.035)。3箇月後治療組激素不良反應僅錶現為體重增加,無其他嚴重不良反應。結論短期應用小劑量潑尼鬆治療DMD可以增加患兒肌力,改善患兒運動及肺功能。
목적:평고단기응용소제량당피질격소시부구유제고Duchenne형기영양불량(Duchenne muscular dystrophy, DMD)환인기력화운동공능적작용。방법납입2005년9월지2008년12월북경협화의원명학진단적5~10세DMD환인。시험채취수궤、쌍맹、대조적원칙,분위치료조화대조조。치료조환인급여발니송0.75 mg/(kg· d),대조조급여유생소C 0.3 mg/d。치료시간위3개월,매격1개월수방1차,수방3개월,평고4차취진시적기력、운동공능、폐공능화기산격매。결과공31례DMD환인납입연구,기중치료조17례,대조조14례。대조조환인4차취진적평균기력평분의차위38.2±7.5、37.0±8.0、36.2±7.6、36.6±7.7,치료조위37.7±6.1、39.1±6.4、40.3±5.9、40.0±5.6,량조치료1、2、3개월후여치료전기력적차치비교,차이균유통계학의의(P=0.024, P=0.000, P=0.002)。대조조4차취진행주9 m적평균시간의차위(7.7±2.5)、(7.6±2.8)、(8.1±2.4)、(7.6±2.8) s,치료조위(8.5±3.4)、(7.2±3.3)、(7.6±3.1)、(7.1±2.8) s,량조치료2、3개월후여치료전행주9 m소용시간적차치비교,차이균유통계학의의(P=0.013, P=0.003)。대조조4차취진적평균용력폐활량(forced vital capacity, FVC)의차위(1.24±0.28)、(1.13±0.26)、(1.21±0.31)、(1.16±0.26) L,치료조위(1.14±0.37)、(1.40±0.35)、(1.42±0.36)、(1.52±0.37) L,량조치료1、2、3개월후여치료전FVC적차치비교,차이균유통계학의의(P=0.000, P=0.006, P=0.000)。량조치료1개월후여치료전적기산격매적차치비교,차이역유통계학의의( P=0.035)。3개월후치료조격소불량반응부표현위체중증가,무기타엄중불량반응。결론단기응용소제량발니송치료DMD가이증가환인기력,개선환인운동급폐공능。
Objective To assess whether low dose corticosteroid could improve muscle strength and motor function in children with Duchenne muscular dystrophy ( DMD) .Methods In this randomized double-blind con-trolled trial , patients with DMD at the age of 5-10 diagnosed from September 2005 to December 2008 in Peking Union Medical College Hospital were enrolled .The patients were divided into treatment group and control group randomly.The treatment group was given prednisone at a dosage of 0.75 mg/(kg· d) for three months, and the control group was given vitamin C 0.3 mg/d as placebo in the same period .Every patient was followed-up once a month for a total of 4 times, testing muscle strength , motor function ( 9-meter walk test ) , respiratory function [forced vital capacity (FVC)], and serum creatine kinase .Results Thirty-one eligible DMD patients were en-rolled, including 17 in the treatment group and 14 in the control group.The mean muscle strength scores of the con-trol group at the 4 clinic visits were 38.2 ±7.5, 37.0 ±8.0, 36.2 ±7.6, and 36.6 ±7.7, while those of the treat-ment group were 37.7 ±6.1, 39.1 ±6.4, 40.3 ±5.9, and 40.0 ±5.6, respectively .The changes in muscle strength scores at 1, 2, 3 months after treatment compared with the scores at diagnosis were all significantly larger in the treatment group than in the control group (P=0.024, P=0.000, P=0.002).The mean time of 9-meter walk at the 4 visits in the control group were (7.7 ±2.5), (7.6 ±2.8), (8.1 ±2.4), and (7.6 ±2.8) s, and those in the treatment group were (8.5 ±3.4), (7.2 ±3.3), (7.6 ±3.1), and (7.1 ±2.8) s, showing signifi-cantly larger changes of time in the treatment group than in the control group at 2 and 3 months after treatment com-pared with the time at diagnosis ( P=0.013, P=0.003) .The four mean FVCs in the control group were (1.24 ± 0.28), (1.13 ±0.26), (1.21 ±0.31), and (1.16 ±0.26) L, and the mean FVCs in the treatment group were (1.14 ±0.37), (1.40 ±0.35), (1.42 ±0.36), and (1.52 ±0.37) L, showing significantly larger changes in the treatment group than in the control group at 1, 2, and 3 months after treatment compared with the FVCs at diag-nosis (P=0.000, P=0.006, P=0.000).The decrease of creatine kinase in the treatment group was significantly larger after 1-month treatment than that in the control group (P=0.035).There were no serious adverse effects in the treatment group except weight gain .Conclusions Short-term application of low dose prednisone in children with DMD can increase muscle strength , improve motor and respiratory functions .